Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma
Abstract Background Circulating long non-coding RNAs (lncRNAs) have been demonstrated to serve as diagnostic or prognosis biomarkers for various disease. We aimed to elucidate the diagnostic efficacy of serum lncRNA SCARNA10 for the hepatocellular carcinoma (HCC). Methods In this study, a total of 1...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-09530-3 |
| _version_ | 1817990943219908608 |
|---|---|
| author | Yawei Han Wenna Jiang Yu Wang Meng Zhao Yueguo Li Li Ren |
| author_facet | Yawei Han Wenna Jiang Yu Wang Meng Zhao Yueguo Li Li Ren |
| author_sort | Yawei Han |
| collection | DOAJ |
| description | Abstract Background Circulating long non-coding RNAs (lncRNAs) have been demonstrated to serve as diagnostic or prognosis biomarkers for various disease. We aimed to elucidate the diagnostic efficacy of serum lncRNA SCARNA10 for the hepatocellular carcinoma (HCC). Methods In this study, a total of 182 patients with HCC, 105 patients with benign liver disease (BLD), and 149 healthy controls (HC) were enrolled. According to different classifications, the levels of serum SCARNA10 were assessed by quantitative real-time polymerase chain reaction (qPCR). The correlations between serum SCARNA10 and clinicopathological characteristics were further analyzed. The receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to estimate the diagnostic capacity of serum SCARNA10 and its combination with AFP for HCC. Results The results demonstrated that the levels of serum SCARNA10 were significantly higher in HCC patients than in patients with BLD and healthy controls, and significantly increased in HCC patients with hepatitis B or C infection, or with liver cirrhosis. Furthermore, positive correlations were noted between serum SCARNA10 level and some clinicopathological characteristics, including tumor size, differentiation degrees, tumor stage, vascular invasion, tumor metastasis and complications. ROC analysis revealed that SCARNA10 had a significantly predictive value for HCC (Sensitivity = 0.70, Specificity = 0.77, and AUC = 0.82), the combination of SCARNA10 and AFP gained the higher sensitivity (AUCSCARNA10 + AFP = 0.92 vs AUCAFP = 0.83, p < 0.01). SCARNA10 retained significant diagnosis capabilities for AFP-negative HCC patients. Conclusions In summary, lncRNA SCARNA10 may serve as a novel and non-invasive biomarker with relatively high sensitivity and specificity for HCC diagnosis. |
| first_indexed | 2024-04-14T01:06:43Z |
| format | Article |
| id | doaj.art-e26b7f708d534845b3595a5499cc2b9c |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-14T01:06:43Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-e26b7f708d534845b3595a5499cc2b9c2022-12-22T02:21:13ZengBMCBMC Cancer1471-24072022-04-012211810.1186/s12885-022-09530-3Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinomaYawei Han0Wenna Jiang1Yu Wang2Meng Zhao3Yueguo Li4Li Ren5Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for CancerDepartment of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for CancerDepartment of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for CancerDepartment of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for CancerDepartment of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for CancerDepartment of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for CancerAbstract Background Circulating long non-coding RNAs (lncRNAs) have been demonstrated to serve as diagnostic or prognosis biomarkers for various disease. We aimed to elucidate the diagnostic efficacy of serum lncRNA SCARNA10 for the hepatocellular carcinoma (HCC). Methods In this study, a total of 182 patients with HCC, 105 patients with benign liver disease (BLD), and 149 healthy controls (HC) were enrolled. According to different classifications, the levels of serum SCARNA10 were assessed by quantitative real-time polymerase chain reaction (qPCR). The correlations between serum SCARNA10 and clinicopathological characteristics were further analyzed. The receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to estimate the diagnostic capacity of serum SCARNA10 and its combination with AFP for HCC. Results The results demonstrated that the levels of serum SCARNA10 were significantly higher in HCC patients than in patients with BLD and healthy controls, and significantly increased in HCC patients with hepatitis B or C infection, or with liver cirrhosis. Furthermore, positive correlations were noted between serum SCARNA10 level and some clinicopathological characteristics, including tumor size, differentiation degrees, tumor stage, vascular invasion, tumor metastasis and complications. ROC analysis revealed that SCARNA10 had a significantly predictive value for HCC (Sensitivity = 0.70, Specificity = 0.77, and AUC = 0.82), the combination of SCARNA10 and AFP gained the higher sensitivity (AUCSCARNA10 + AFP = 0.92 vs AUCAFP = 0.83, p < 0.01). SCARNA10 retained significant diagnosis capabilities for AFP-negative HCC patients. Conclusions In summary, lncRNA SCARNA10 may serve as a novel and non-invasive biomarker with relatively high sensitivity and specificity for HCC diagnosis.https://doi.org/10.1186/s12885-022-09530-3Hepatocellular carcinomaLong non-coding RNASCARNA10Biomarker |
| spellingShingle | Yawei Han Wenna Jiang Yu Wang Meng Zhao Yueguo Li Li Ren Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma BMC Cancer Hepatocellular carcinoma Long non-coding RNA SCARNA10 Biomarker |
| title | Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma |
| title_full | Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma |
| title_fullStr | Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma |
| title_full_unstemmed | Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma |
| title_short | Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma |
| title_sort | serum long non coding rna scarna10 serves as a potential diagnostic biomarker for hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Long non-coding RNA SCARNA10 Biomarker |
| url | https://doi.org/10.1186/s12885-022-09530-3 |
| work_keys_str_mv | AT yaweihan serumlongnoncodingrnascarna10servesasapotentialdiagnosticbiomarkerforhepatocellularcarcinoma AT wennajiang serumlongnoncodingrnascarna10servesasapotentialdiagnosticbiomarkerforhepatocellularcarcinoma AT yuwang serumlongnoncodingrnascarna10servesasapotentialdiagnosticbiomarkerforhepatocellularcarcinoma AT mengzhao serumlongnoncodingrnascarna10servesasapotentialdiagnosticbiomarkerforhepatocellularcarcinoma AT yueguoli serumlongnoncodingrnascarna10servesasapotentialdiagnosticbiomarkerforhepatocellularcarcinoma AT liren serumlongnoncodingrnascarna10servesasapotentialdiagnosticbiomarkerforhepatocellularcarcinoma |